Archived Bulletins

November 15, 2017

Published: November 15, 2017
Category: Trials
OVC.1 (NRG GY004) A Phase III Study Comparing Single-agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-based Chemotherapy in Women with Recurrent Platinum-sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer has been closed to accrual as of Nov 10, 2017.
 
Read More

Published: November 15, 2017
Category: Trials

Celebrating a fantastic milestone for the CX.5 SHAPE trial with over 400 patients randomized world wide.

Read More

Published: November 15, 2017
Category: Trials

Trial citations

Read More

Published: November 15, 2017
Category: Trials

The MEC.5 trial, A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma, is closed further accrual as of November 2nd, 2017. This trial met its accrual goal and was subsequently closed to registrations.

Read More

November 01, 2017

Published: November 01, 2017
Category: Trials
GAC.1 trial: Phase III Randomized Study of Adjuvant Chemoradiation After Resection in Patients with Gastric or Gastroesophageal Adenocarcinoma, has been permanently closed by the lead group.
 
Read More

Published: November 01, 2017
Category: News
Award recipients

Canadian Cancer Research Alliance has announced the recipients of their 2017 awards: former CCTG Director, Dr. Elizabeth Eisenhauer (Queen's University) will recieve the Exceptional Leadership in Cancer Research award and Ms. Judy Needham (Canadian Cancer Trials Group and Canadian Cancer Clinical Trials Network) will receive the Exceptional Leadership in Patient Involvement in Cancer award.

Read More

Published: November 01, 2017
Category: News

Introducing the new CCTG Group Bulletin format, please share your thoughts with us so we can make adjustments and improvements.

Read More

Published: November 01, 2017
Category: Publications

Primary publications for CCTG clinical trials GAC.1 and IND.213

Read More